Adjuvant Endocrine Therapy and Risk of Contralateral Breast Cancer
Interview with Gretchen L. Gierach, PhD, author of Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"JAMA Oncology Author Interviews","authorlink":""},"src":"http:\/\/traffic.libsyn.com\/jamaoncologyauthorinterviews\/Adjuvant_Endocrine_Therapy_and_Risk_of_Contralateral_Breast_Cancer_JAMA_Oncology.mp3?dest-id=422099","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202106\/2d36c0-4594-fc93-a50181_800.jpg"},"title":"Adjuvant Endocrine Therapy and Risk of Contralateral Breast Cancer","link":"javascript:;","id":"item-438014"}]
